Clear Search sequence regions


  • apoptosis (1)
  • cohort (1)
  • cytopenias (1)
  • diagnosis (2)
  • exons (1)
  • fas receptor (2)
  • humans (1)
  • lymphocyte (1)
  • pathogenesis (1)
  • Sizes of these terms reflect their relevance to your search.

    Autoimmune lymphoproliferative syndrome (ALPS) is characterized by chronic nonmalignant lymphadenopathy, splenomegaly, cytopenias, and other autoimmune manifestations. ALPS is caused by lymphocyte accumulation from defects in FAS-mediated apoptosis. Heterozygous germline or somatic pathogenic single nucleotide variants in FAS are the most common molecular etiology of ALPS. Through the Centralized Sequencing Program at the National Institute of Allergy and Infectious Diseases, we performed exome sequencing on subjects with a clinical diagnosis of ALPS, with a subset receiving copy number variant (CNV) analysis. In this cohort, we identified 3 subjects from unrelated families with CNVs at the FAS locus. One subject had a de novo ∼0.828 Mb copy number loss encompassing all of FAS. The second subject had a maternally inherited ∼1.004 Mb copy number loss encompassing all of FAS. The third subject had a paternally inherited ∼0.044 Mb copy number loss encompassing exons 7 through 9 of FAS. Subjects with deletions in FAS had clinical presentations and biomarker profiles similar to those with ALPS and with germline and somatic FAS variants. We demonstrate that CNV analysis should be pursued if there is clinical and biomarker evidence of ALPS because it can lead to a molecular diagnosis and appropriate treatment when FAS sequencing is inconclusive. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

    Citation

    Kathleen Jevtich, Susan Price, Morgan Similuk, Elaine Kulm, Jia Yan, Michael Setzer, Leila Jamal, Luis M Franco, Rajarshi Ghosh, Magdalena Walkiewicz, V Koneti Rao. The contribution of rare copy number variants in FAS toward pathogenesis of autoimmune lymphoproliferative syndrome. Blood advances. 2022 Jul 12;6(13):3974-3978

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35476126

    View Full Text